Takeda Pharmaceutical Company Ltd

🇸🇪Sweden

Country: 🇸🇪Sweden

Ownership: -

Established: 1925-01-01

Employees: -

Market Cap: $47.5B

Website: http://www.takeda.co.jp/

Clinical Trials

A Study of Vedolizumab and Biologic Agents in Participants With Inflammatory Bowel Disease (IBD)

Completed

Conditions: Inflammatory Bowel Disease (IBD)
Ulcerative Colitis
Crohn's Disease

First Posted Date: 2022-10-27

Last Posted Date: 2023-01-19

Lead Sponsor: Takeda

Target Recruit Count: 423

Registration Number: NCT05596422

Locations: 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan
🇨🇳
China Medical University Hospital, Taichung, Taiwan
🇨🇳
Chang Gung Memorial Hospital-Linkou, Taoyuan, Taiwan

and more 1 locations

A Study of Modakafusp Alfa Together With Daratumumab Adults With Relapsed or Refractory Multiple Myeloma

Phase 1

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Modakafusp Alfa
Drug: Daratumumab

First Posted Date: 2022-10-21

Last Posted Date: 2024-04-03

Lead Sponsor: Takeda

Target Recruit Count: 58

Registration Number: NCT05590377

Locations: 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸
HCA Midwest Health (Midwest Ventures Group HCA MidAmerica Division), Overland Park, Kansas, United States
🇺🇸
Fort Wayne Medical Oncology and Hematology, Inc, Fort Wayne, Indiana, United States

and more 24 locations

A Study of Recombinant Von Willebrand Factor (rVWF) (TAK-577) in Children With Severe Von Willebrand Disease (vWD)

Phase 3

Recruiting

Conditions: Von Willebrand Disease (VWD)

Interventions: Biological: Recombinant von Willebrand Factor (rVWF)
Biological: ADVATE

First Posted Date: 2022-10-17

Last Posted Date: 2024-12-10

Lead Sponsor: Takeda

Target Recruit Count: 24

Registration Number: NCT05582993

Locations: 🇺🇸
Children's Health Care d/b/a Children's Minnesota, Minneapolis, Minnesota, United States
🇫🇷
Hemostase Clinique - Institut Coeur-Poumons, Lille, France
🇫🇷
Hopital Edouard Herriot - CHU Lyon, Lyon, France

and more 1 locations

A Study to Review the Treatment and Outcomes of Teenagers and Adults With Non-histaminergic Angioedema With Normal C1 Inhibitor in Canada

Completed

Conditions: Hereditary Angioedema (HAE)
Angioedema

Interventions: Other: No Intervention

First Posted Date: 2022-10-13

Last Posted Date: 2024-07-30

Lead Sponsor: Takeda

Target Recruit Count: 60

Registration Number: NCT05578417

Locations: 🇨🇦
CHU de Québec - Université Laval, Quebec, Canada
🇨🇦
Hamilton Health Science Corporation, Hamilton, Ontario, Canada
🇨🇦
University of Manitoba, Winnipeg, Manitoba, Canada

and more 2 locations

A Study on Cytomegalovirus (CMV) Infection Outcomes Among Solid Organ Transplant (SOT) Participants in Europe and Canada

Completed

Conditions: Cytomegalovirus (CMV)

First Posted Date: 2022-10-13

Last Posted Date: 2024-04-25

Lead Sponsor: Takeda

Target Recruit Count: 159

Registration Number: NCT05576805

Locations: 🇦🇹
MU Graz, Graz, Austria
🇦🇹
MU Innsbruck, Innsbruck, Austria
🇮🇹
U Parma, Parma, Italy

and more 12 locations

A Study on Cytomegalovirus (CMV) Infection Outcomes Among Hematopoietic Stem Cell Transplant (HSCT) Participants in Europe and Canada

Completed

Conditions: Cytomegalovirus (CMV)

First Posted Date: 2022-10-07

Last Posted Date: 2024-02-28

Lead Sponsor: Takeda

Target Recruit Count: 118

Registration Number: NCT05571137

Locations: 🇦🇹
MU Graz, Graz, Austria
🇧🇪
UZ Leuven, Leuven, Belgium
🇷🇸
Clinical Center of Vojvodina, Novi Sad, Serbia

and more 8 locations

A Study of TAK-951 in Healthy Adults

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: TAK-951
Drug: TAK-951 Placebo

First Posted Date: 2022-10-05

Last Posted Date: 2023-09-14

Lead Sponsor: Takeda

Target Recruit Count: 128

Registration Number: NCT05567393

Locations: 🇺🇸
California Clinical Trials Medical Group, Glendale, California, United States

A Survey to Assess Participants' and Physicians' Knowledge, Attitudes and Behavior When Using GATTEX

Recruiting

Conditions: Short Bowel Syndrome (SBS)

Interventions: Other: No Intervention

First Posted Date: 2022-09-30

Last Posted Date: 2024-12-04

Lead Sponsor: Takeda

Target Recruit Count: 600

Registration Number: NCT05561647

Locations: 🇺🇸
Shire-NPS Pharmaceuticals, INC., Lexington, Massachusetts, United States

A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma

Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Modakafusp alfa
Drug: Lenalidomide
Drug: Pomalidomide
Drug: Bortezomib
Drug: Carfilzomib
Drug: Daratumumab

First Posted Date: 2022-09-27

Last Posted Date: 2024-12-24

Lead Sponsor: Takeda

Target Recruit Count: 15

Registration Number: NCT05556616

Locations: 🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Gabrail Cancer Center Research, Canton, Ohio, United States
🇺🇸
Scripps Health, San Diego, California, United States

and more 18 locations

A Study of TAK-625 for the Treatment of Progressive Familial Intrahepatic Cholestasis (PFIC)

Phase 3

Active, not recruiting

Conditions: Progressive Familial Intrahepatic Cholestasis (PFIC)

Interventions: Drug: TAK-625

First Posted Date: 2022-09-16

Last Posted Date: 2023-11-07

Lead Sponsor: Takeda

Target Recruit Count: 5

Registration Number: NCT05543187

Locations: 🇯🇵
Yokohamashi Tobu Hospital, Yokohama, Kanagawa, Japan
🇯🇵
Kyoto University Hospital, Kyoto, Japan
🇯🇵
University of Tsukuba Hospital, Tsukuba, Ibaraki, Japan

and more 5 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy